TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Clinical diagnosis of BPH~* AUA-SI \>=12 \[American Urological Association Symptom Index\]~* Qmax \> 5ml/sec and \<=15ml/sec and minimum voided volume of \>=125ml~* Prostate volume \>=30cm(3)~Exclusion:~* Post void residual volume \>250ml~* History or evidence of prostate cancer~* Total serum PSA \<1.5ng/ml or \>10.0ng/ml (Prostate specific antigen)~* Previous prostatic surgery or other invasive procedures to treat BPH.~* History of AUR (Acute Urinary Retention) within 3 months~* History of flexible/rigid cystoscopy or other instrumentation of the urethra within 7 days~* Any causes other than BPH, which may in the judgement of the investigator, result in urinary symptoms or changes in flow rate~* History of hepatic impairment or abnormal liver function tests~* Use of any 5a-reductase inhibitors ,any drugs with antiandrogenic properties or other drugs noted for gynaecomastia effects, or could affect prostate volume, within past 6 months and throughout the study~* Use of alpha-receptor blockers within 2 weeks and throughout the study.~* Use of phytotherapy for BPH within 2 weeks and/or predicted to need phytotherapy during the study.~* Concurrent use of anabolic steroids~* Use of any alpha-adrenergic agonists or cholinergics within 48 hours prior to uroflowmetry assessment.~* Hypersensitivity to any 5a-reductase inhibitor or other chemically-related drugs.~* Actively trying to procreate or unwilling to wear a condom during intercourse with a woman of childbearing potential for duration of participation in this study and 16 weeks following treatment.~* History or current evidence of drug or alcohol abuse within the previous 12 months.~* History of any illness that in the opinion of the investigator might confound the results of the study or poses additional risk to the patient.~* Any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, of cerebrovascular accident within 6 months prior to Screening visit; uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management.~* History of renal insufficiency, or serum creatinine \>1.5xULN (Upper Limit of Normal )~* Participation in any investigational or marketed drug trial within 30 days and during the course of the study.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): dutasteride 0.5mg once daily orally
- B (Type: PLACEBO_COMPARATOR): Placebo matched once daily orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inflammation and Insulin Resistance in Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the American College of Rheumatology (ACR) criteria for the diagnosis of rheumatoid arthritis (RA)~* Stable disease activity, as evidenced by no change in immunomodulating or anti-inflammatory therapy in the 1 month before study entry~* Moderate disease activity, as reflected by a minimum of three swollen and tender joints~* If female of childbearing potential, willing to use effective method of contraception~Exclusion Criteria:~* Allergic to pioglitazone~* Active cancer (other than skin cancer)~* HIV infected~* Currently receiving dialysis~* Received an organ or bone marrow transplant~* Heart failure~* Severe edema, as judged by the principal investigator~* Diabetes mellitus requiring drug therapy: levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than twice the upper limit of normal~* Underwent major surgery in the 3 months before study entry~* Severe comorbid condition that is likely to compromise survival or study participation~* Currently receiving gemfibrozil or rifampin~* Osteoporosis and not receiving osteoporosis medications~* Unwillingness, or other inability, to cooperate with study procedures~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo First (Type: EXPERIMENTAL): Placebo for first 8 weeks, then washout period for 4 weeks, and finally pioglitazone for 8 weeks.
- Pioglitazone First (Type: EXPERIMENTAL): Pioglitazone for first 8 weeks, then washout period for 4 weeks, and finally placebo for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with relapsed and refractory multiple myeloma (as per International Myeloma Working Group \[IMWG\] definitions) whose prior therapy included a proteasome inhibitor and an immunomodulatory agent, being newly initiated on DARZALEX (daratumumab) monotherapy based on independent clinical judgment of treating physicians as per locally approved prescribing information~* Each participant (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study. Participants must be willing and able to adhere to the prohibitions and restrictions specified in this protocol, as referenced in the informed consent form (ICF)~Exclusion Criteria:~* Participants who are not eligible to receive DARZALEX as per the locally approved prescribing information~* Participant participating or planning to participate in any interventional drug trial during the course of this study~* Known seropositive for human immunodeficiency virus (HIV)~* Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen \[HBsAg\]). Participants with resolved infection (that is, participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen \[anti-HBc\] and/or antibodies to hepatitis B surface antigen \[anti-HBs\]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. exception: Participants with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) and a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR~* Known seropositive for hepatitis C (except in the setting of a sustained virologic response \[SVR\], defined as aviremia at least 12 weeks after completion of antiviral therapy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daratumumab (Type: EXPERIMENTAL): Participants will receive 16 milligram per kilogram (mg/kg) of daratumumab as intravenous (IV) infusion every week (QW) in Cycles 1 and 2 (Days 1, 8, 15 and 22) and every 2 weeks (Q2W) in Cycle 3 to 6 (Days 1 and 15) each cycle is of 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Baclofen to Reduce Alcohol Use in Veterans With HCV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Criteria for Participation Include if:~* Male or female~* Age 18 or older~Medical record shows:~* Serum antibody positive for HCV and PCR (Polymerase Chain Reaction) confirmation, Men or Women: \> 7 drinks per week for each of the proceeding 2 weeks Or One heavy drinking day per week for 2 weeks (Heavy drinking day: 5 drinks in one day for men and \>4 drinks in one day for women) based on Timeline Followback method (TLFB)~* Alcohol use Disorder (abuse or dependence) based on Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (SCID)~  * Yes Medical record and self report~ * Medical record, self report, SCID, Beck Depression Inventory -II (BDI-II)~ * Able to attend clinic appointments~ * Yes No Self-report~Exclusion Criteria:~Criteria for Participation Exclude if:~* Male or female~* Under age 18~* Cocaine, methamphetamine or opioid dependence within the past 6 months\*~* Any known pre-existing medical conditions that could interfere with participation in the protocol, such as:~  * Central Nervous System (CNS) trauma~ * Known cognitive impairment~ * Dementia~ * Encephalopathy from liver disease~ * Acute psychiatric instability, such as significant psychosis, mania, or elevated risk for suicide~* Not able to attend clinic appointments~* Pregnant women~* If any of the following medication are being used:~  * Ondansetron~ * Disulfiram~ * Topiramate~ * Naltrexone~ * Acamprosate~ * Buprenorphine~ * Methadone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baclofen (Type: EXPERIMENTAL): baclofen 10 mg po tid
- Placebo (Type: PLACEBO_COMPARATOR): placebo given tid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants in good health~Exclusion Criteria:~* Previous administration of any oral poliovirus vaccine (OPV) and rotavirus vaccine~* Receipt of inactivated poliovirus vaccine (IPV) prior to the first dose of either study vaccine, or at any time during the course of the study~* Any condition resulting in depressed immunity~* Any allergy to any vaccine component as stated in the package circulars~* Allergies to polymyxin B, neomycin or any other antibiotics~* Receipt of intramuscular, oral, or intravenous corticosteroid treatment~* History of congenital abdominal disorders, intussusception, or abdominal surgery; clinical evidence of active gastrointestinal illness~* History of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to thrive~* Prior receipt of a blood transfusion or blood products, including immunoglobulin~* Fever, with a rectal temperature of ≥38.1°C (≥ 100.5°F) at the time of immunization~* Infants residing in a household with an immunocompromised person

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): RotaTeq and OPV concomitantly
- 2 (Type: EXPERIMENTAL): RotaTeq and OPV on staggered schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with documented chronic hepatitis C infection as evidenced by presence of HCV antibody at least 6 months (180 days) prior to the informed consent. - Participants with genotype 1 HCV infection. - Participants with plasma HCV RNA level of ≥ 5.0 log10 IU/mL at screening.~Exclusion Criteria:~* Participants diagnosed with hepatic cirrhosis or hepatic failure. - Participants with any other liver disease than hepatitis C. - Participants with infection/co-infection with non-genotype 1 HCV.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TMC12/PR24 50 mg (Type: EXPERIMENTAL): Participants received TMC435 50 mg once daily with PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24 Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
- TMC12/PR24 100 mg (Type: EXPERIMENTAL): Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
- TMC24/PR24 50 mg (Type: EXPERIMENTAL): Participants received TMC435 50 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435, PR) at Week 24. All other participants continued PR until Week 48.
- TMC24/PR24 100 mg (Type: EXPERIMENTAL): Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
- PR48 Control (Type: EXPERIMENTAL): Participants received PegIFNa-2a and ribavirin (PR) for 48 weeks (PR48 control group)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a diagnosis of rheumatoid arthritis (RA) \[2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria\] , and are ACR functional class I-III.~* Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and ≥ 6 tender joints (from a tender joint count based on 68 joints (TJC68)) at both screening and Day 1.~* Ongoing treatment with a stable dose of MTX~Key Exclusion Criteria:~* Previous treatment with any janus kinase (JAK) inhibitor~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Filgotinib 200 mg (Type: EXPERIMENTAL): Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of methotrexate (MTX)
- Filgotinib 100 mg (Type: EXPERIMENTAL): Filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX
- Adalimumab (Type: ACTIVE_COMPARATOR): Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + adalimumab 40 mg in addition to a stable dose of MTX
- Placebo to Filgotinib 200 mg (Type: EXPERIMENTAL): Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 200 mg to receive filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
- Placebo to Filgotinib 100 mg (Type: EXPERIMENTAL): Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 100 mg to receive filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
- Placebo Never Received Filgotinib (Type: PLACEBO_COMPARATOR): Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo cardiac surgery with cardiopulmonary bypass and modified ultrafiltration~* age greater than 18 years old~* penicillin allergy or in-hospital stay greater than 24 hours~* normal renal function~* normal liver function~* absence of clinical and laboratory signs of infection~Exclusion Criteria:~* vancomycin allergy~* pregnancy~* impaired renal function~* impaired liver function~* morbid obesity~* active infections~* Jehovah's Witness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Vancomycin concentrations (Type: OTHER): Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alabama Veterans Rural Health Initiative

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans who live in rural Alabama counties who have either never enrolled or have previously enrolled but have not accessed a VA in 2 years or more~* Signed informed consent~* Any race, social class or ethnicity~Exclusion Criteria:~* Pending active legal charges or current/expected incarceration

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Enhanced Engagement and Enrollment (EEE) (Type: EXPERIMENTAL): Enhanced Engagement and Enrollment (EEE) consists of the outreach worker (interventionalist) engaging the participant in education (about VA resources and medical care), navigating the patient through the VA eligibility, enrollment, and scheduling processes, and using motivational interview to focus on ambivalence about attending a VA appointment.
- Administrative Outreach (AO) (Type: ACTIVE_COMPARATOR): Administrative Outreach (AO) consists of the outreach worker giving the participants an application package to VA enrollment or phone number for the scheduling clerk. This intervention does not involve education, patient navigation (guidance through VA eligibility, enrollment, and scheduling processes) or motivational interviews (interviews focused on ambivalence about attending a VA appointment).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI ≥ 28 kg/m² and \< 45 kg/m²~* Waist circumference \> 80 cm (women) \> 94 cm (men)~Exclusion Criteria:~* Energy intake lower than the standard value according to Miffin St-Jeor equation~* Pregnancy or breast-feeding~* Addiction to alcohol~* Inability to fulfil the requirement of the trial protocol~* Cancer ,malignant tumour~* Hypersensitivity reactions to crustaceans or ingredient of the study medication~* Chronic diseases not under control with adequate therapy~* Diabetes

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Drug: orlistat 60mg capsules (Type: ACTIVE_COMPARATOR): A tailored blister-strip for one day contains~* three capsules with orlistat 60mg Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~* six placebo tablets Administration: 3 times daily 2 tablets with each main meal
- Medical device: polyglucosamine (Type: ACTIVE_COMPARATOR): A tailored blister-strip for one day contains~* three placebo capsules Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~* six tablets Administration: 3 times daily 2 tablets (whereas the 2 tablets in the mold breakfast are placebo tablets and the remaining 4 tablets for lunch and dinner contains poliglucosamine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete